RxDoctor Payments Data

Cheryl Habeck, NP

Family · Menasha, WINPI 1114912425

Payments from drug & device makers

$2,325in general payments, 2019–2025

Across 115 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$546
  • Medtronic$514
  • BETA Bionics, Inc.$489
  • Abbott$274
  • Dexcom, Inc.$190
  • Insulet Corporation$113
  • plus $199 from 6 others

What the payments were for

  • Food & beverage$2,325100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,325 in reported general payments places this provider in the 90th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$17,929
Medicare patients
83
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide250$276,510
JardianceEmpagliflozin255$251,067
TrulicityDulaglutide100$125,966
Humulin R U-500 KwikpenInsulin Regular, Human37$88,210
MounjaroTirzepatide66$78,564
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog84$68,439
Soliqua 100-33Insulin Glargine/Lixisenatide57$60,425
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog66$57,967
RybelsusSemaglutide42$47,791
Tresiba Flextouch U-100Insulin Degludec67$47,490
Tresiba Flextouch U-200Insulin Degludec31$47,262
Lantus SolostarInsulin Glargine,hum.Rec.Anlog279$45,686
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/747$43,786
Insulin Aspart FlexpenInsulin Aspart142$39,569
Humalog Kwikpen U-200Insulin Lispro11$32,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog, Fiasp$85$350,297360 claims
Boehringer IngelheimJardiance$27$251,067255 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$546$67,82198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,273 family providers in Wisconsin.

Other family in Menasha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →